ERBB2 and breast carcinoma: Estrogenic signaling is known to interact with immune activity and it has been suggested that immune activity might be reduced in HER2 + /HR + breast cancer [28]. The results of the present study together with these previous findings highlight the importance of recognizing that HER2 + Luminal B breast cancer and HER2 + /HR- breast cancer are two different entities.